Considering JNHB for market access in the Nordics? NHTA supports companies in evaluating the benefits of this joint approach and is actively involved in several JNHB submissions.
Insights
Joint Nordic HTA-Bodies (JNHB)
21Considering submitting through JNHB (Joint Nordic HTA-Bodies)?
Are you unsure whether the potential benefits of submitting through the JNHB outweigh the potential risks compared to a national approach?
NHTA has comprehensive experience in assessing the optimal access pathway and executing drug launches in the Nordics, and we are currently supporting with several JNHB processes.
Want to hear more about the JNHB and whether this process may be relevant for you? Reach out to Asger Lindvig: al@nhta.com
